Long And Winding Road To MEK Inhibition
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Early MEK inhibitors failed in trials for a variety of reasons, including adverse events. GlaxoSmithKline designed its development program for trametinib, which just performed well in Phase III, with lessons learned from trials of other drugs.